Evonik Industries’ (EVKIF) Sell Rating Reiterated at UBS Group

UBS Group reaffirmed their sell rating on shares of Evonik Industries (OTCMKTS:EVKIF) in a research report sent to investors on Wednesday morning, The Fly reports.

Several other research firms have also weighed in on EVKIF. Barclays raised Evonik Industries from an equal weight rating to an overweight rating in a research report on Wednesday, February 5th. JPMorgan Chase & Co. restated an overweight rating on shares of Evonik Industries in a research note on Tuesday, March 24th. Finally, Morgan Stanley restated an overweight rating on shares of Evonik Industries in a research note on Monday, March 30th. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company. Evonik Industries has an average rating of Buy.

Shares of EVKIF opened at $24.19 on Wednesday. Evonik Industries has a 52-week low of $17.32 and a 52-week high of $30.72. The stock has a 50 day moving average price of $23.47 and a 200 day moving average price of $25.83.

Evonik Industries Company Profile

Evonik Industries AG engages in the specialty chemicals business worldwide. It operates through Nutrition & Care, Resource Efficiency, Performance Materials, and Services segments. The Nutrition & Care segment offers specialty chemicals, including amphoteric surfactants, ceramides, phytosphingosines, oleochemicals, quaternary derivatives, polyurethane additives, organically modified silicones, superabsorbents, amino acids and amino acid derivatives, synthesis products, pharmaceutical polymers, and DL-methionine for use in consumer goods, and animal nutrition and healthcare products.

See Also: What is the Nikkei 225 index?    

The Fly

Analyst Recommendations for Evonik Industries (OTCMKTS:EVKIF)

Receive News & Ratings for Evonik Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evonik Industries and related companies with MarketBeat.com's FREE daily email newsletter.